{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:17Z","timestamp":1792622597948,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K08-AR070285-01"],"award-info":[{"award-number":["K08-AR070285-01"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["5R03AR066343-02"],"award-info":[{"award-number":["5R03AR066343-02"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR42309"],"award-info":[{"award-number":["R01 AR42309"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K12 HD055884"],"award-info":[{"award-number":["K12 HD055884"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1630-z","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T15:02:34Z","timestamp":1531321354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-2628","authenticated-orcid":false,"given":"Benjamin","family":"Korman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Goncalves","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold","family":"Olefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Tourtellotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"issue":"3","key":"1630_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557\u201367.","journal-title":"J Clin Invest"},{"issue":"3","key":"1630_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017;2(3):137\u201352.","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"1630_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011;8(1):42\u201354.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1630_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.stem.2017.07.011","volume":"21","author":"E El Agha","year":"2017","unstructured":"El Agha E, Kramann R, Schneider RK, Li X, Seeger W, Humphreys BD, Bellusci S. Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21(2):166\u201377.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"1630_CR5","doi-asserted-by":"publisher","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","volume":"5","author":"J Wei","year":"2010","unstructured":"Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, Jain M, Whitfield ML, Feghali-Bostwick C, Varga J. PPAR \u03b3 downregulation by TGF-\u03b2 in fibroblasts and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One. 2010;5(11):e13778.","journal-title":"PLoS One"},{"issue":"5","key":"1630_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557\u201366.","journal-title":"Nat Med"},{"issue":"6","key":"1630_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/BOR.0b013e32833de1a7","volume":"22","author":"J Wei","year":"2010","unstructured":"Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor \u03b3: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol. 2010;22(6):671\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"1630_CR8","doi-asserted-by":"publisher","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","volume":"5","author":"J Wei","year":"2010","unstructured":"Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, Jain M, Whitfield ML, Feghali-Bostwick C, Varga J. PPAR\u03b3 downregulation by TGF\u03b2 in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One. 2010;5(11):e13778.","journal-title":"PLoS One"},{"issue":"4","key":"1630_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.20104","volume":"50","author":"AK Ghosh","year":"2004","unstructured":"Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor \u03b2 signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor \u03b3. Arthritis Rheum. 2004;50(4):1305\u201318.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1630_CR10","doi-asserted-by":"publisher","first-page":"L1146","DOI":"10.1152\/ajplung.00383.2004","volume":"288","author":"HA Burgess","year":"2005","unstructured":"Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ. PPAR\u03b3 agonists inhibit TGF-\u03b2 induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1146\u201353.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"1630_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/rheumatology\/kep371","volume":"49","author":"X Shi-wen","year":"2010","unstructured":"Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford). 2010;49(2):259\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1630_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/eurjhf\/hfp048","volume":"11","author":"A Kis","year":"2009","unstructured":"Kis A, Murdoch C, Zhang M, Siva A, Rodriguez-Cuenca S, Carobbio S, Lukasik A, Blount M, O'Rahilly S, Gray SL, et al. Defective peroxisomal proliferators activated receptor \u03b3 activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail. 2009;11(6):533\u201341.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"1630_CR13","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","volume":"75","author":"N Ruzehaji","year":"2016","unstructured":"Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, Luccarini JM, Broqua P, Junien JL, Allanore Y. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016;75(12):2175\u201383.","journal-title":"Ann Rheum Dis"},{"key":"1630_CR14","first-page":"174","volume":"8","author":"R Lee","year":"2017","unstructured":"Lee R, Reese C, Carmen-Lopez G, Perry B, Bonner M, Zemskova M, Wilson CL, Helke KL, Silver RM, Hoffman S, et al. Deficient Adipogenesis of scleroderma patient and healthy African American monocytes. Front Pharmacol. 2017;8:174.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1630_CR15","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/art.24761","volume":"60","author":"M Kapoor","year":"2009","unstructured":"Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor \u03b3 in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum. 2009;60(9):2822\u20139.","journal-title":"Arthritis Rheum"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-015-0641-2","volume":"17","author":"RG Marangoni","year":"2015","unstructured":"Marangoni RG, Korman BD, Allanore Y, Dieude P, Armstrong LL, Rzhetskaya M, Hinchcliff M, Carns M, Podlusky S, Shah SJ, et al. A candidate gene study reveals association between a variant of the peroxisome proliferator-activated receptor \u03b3 (PPAR-\u03b3) gene and systemic sclerosis. Arthritis Res Ther. 2015;17:128.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1630_CR17","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/ar4432","volume":"16","author":"E Lopez-Isac","year":"2014","unstructured":"Lopez-Isac E, Bossini-Castillo L, Simeon CP, Egurbide MV, Alegre-Sancho JJ, Callejas JL, Roman-Ivorra JA, Freire M, Beretta L, Santaniello A, et al. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res Ther. 2014;16(1):R6.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1630_CR18","doi-asserted-by":"publisher","first-page":"e0114017","DOI":"10.1371\/journal.pone.0114017","volume":"10","author":"ME Johnson","year":"2015","unstructured":"Johnson ME, Mahoney JM, Taroni J, Sargent JL, Marmarelis E, Wu MR, Varga J, Hinchcliff ME, Whitfield ML. Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS One. 2015;10(1):e0114017.","journal-title":"PLoS One"},{"issue":"2","key":"1630_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","volume":"174","author":"M Wu","year":"2009","unstructured":"Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-\u03b3. Am J Pathol. 2009;174(2):519\u201333.","journal-title":"Am J Pathol"},{"issue":"7305","key":"1630_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5. Nature. 2010;466(7305):451\u20136.","journal-title":"Nature"},{"issue":"2","key":"1630_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bcp.2005.03.033","volume":"70","author":"DL Feinstein","year":"2005","unstructured":"Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol. 2005;70(2):177\u201388.","journal-title":"Biochem Pharmacol"},{"issue":"5\u20136","key":"1630_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1440-1681.2008.05088.x","volume":"36","author":"RS Mughal","year":"2009","unstructured":"Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE. Peroxisome proliferator-activated receptor \u03b3-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin Exp Pharmacol Physiol. 2009;36(5\u20136):478\u201386.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"1630_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/14740338.2013.741585","volume":"12","author":"M Bortolini","year":"2013","unstructured":"Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf. 2013;12(1):65\u201379.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"1630_CR24","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1194\/jlr.R024505","volume":"53","author":"JV Huang","year":"2012","unstructured":"Huang JV, Greyson CR, Schwartz GG. PPAR-\u03b3 as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res. 2012;53(9):1738\u201354.","journal-title":"J Lipid Res"},{"key":"1630_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPAR\u03b3. Annu Rev Biochem. 2008;77:289\u2013312.","journal-title":"Annu Rev Biochem"},{"issue":"14","key":"1630_CR26","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1074\/jbc.M409468200","volume":"280","author":"C Yu","year":"2005","unstructured":"Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor \u03b3 transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem. 2005;280(14):13600\u20135.","journal-title":"J Biol Chem"},{"issue":"8","key":"1630_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1101\/gad.214023.113","volume":"27","author":"A Mottis","year":"2013","unstructured":"Mottis A, Mouchiroud L, Auwerx J. Emerging roles of the corepressors NCoR1 and SMRT in homeostasis. Genes Dev. 2013;27(8):819\u201335.","journal-title":"Genes Dev"},{"issue":"4","key":"1630_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cell.2011.09.050","volume":"147","author":"P Li","year":"2011","unstructured":"Li P, Fan W, Xu J, Lu M, Yamamoto H, Auwerx J, Sears DD, Talukdar S, Oh D, Chen A, et al. Adipocyte NCoR knockout decreases PPAR\u03b3 phosphorylation and enhances PPAR\u03b3 activity and insulin sensitivity. Cell. 2011;147(4):815\u201326.","journal-title":"Cell"},{"issue":"6","key":"1630_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1101\/gad.1773109","volume":"23","author":"S Ghisletti","year":"2009","unstructured":"Ghisletti S, Huang W, Jepsen K, Benner C, Hardiman G, Rosenfeld MG, Glass CK. Cooperative NCoR\/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009;23(6):681\u201393.","journal-title":"Genes Dev"},{"key":"1630_CR30","first-page":"407","volume":"8","author":"A Zien","year":"2000","unstructured":"Zien A, Kuffner R, Zimmer R, Lengauer T. Analysis of gene expression data with pathway scores. Proc Int Conf Intell Syst Mol Biol. 2000;8:407\u201317.","journal-title":"Proc Int Conf Intell Syst Mol Biol"},{"issue":"3","key":"1630_CR31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/jid.2009.318","volume":"130","author":"JL Sargent","year":"2010","unstructured":"Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML, TGF\u03b2-responsive A. gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130(3):694\u2013705.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1630_CR32","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/art.38990","volume":"67","author":"RG Marangoni","year":"2015","unstructured":"Marangoni RG, Korman B, Wei J, Wood TA, Graham L, Whitfield ML, Scherer PE, Tourtellotte WG, Varga J. Myofibroblasts in cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol. 2015;67(4):1062\u201373.","journal-title":"Arthritis Rheumatol"},{"key":"1630_CR33","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1038\/ncomms11703","volume":"7","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, et al. Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016;7:11703.","journal-title":"Nat Commun"},{"issue":"232","key":"1630_CR34","doi-asserted-by":"publisher","first-page":"232ra250","DOI":"10.1126\/scitranslmed.3008264","volume":"6","author":"S Bhattacharyya","year":"2014","unstructured":"Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, White ES, Varga J. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med. 2014;6(232):232ra250.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1630_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"issue":"1","key":"1630_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","volume":"182","author":"S Bhattacharyya","year":"2013","unstructured":"Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, et al. Toll-like receptor 4 signaling augments transforming growth factor-\u03b2 responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol. 2013;182(1):192\u2013205.","journal-title":"Am J Pathol"},{"issue":"7","key":"1630_CR37","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125(7):2795\u2013807.","journal-title":"J Clin Invest"},{"issue":"1","key":"1630_CR38","first-page":"84","volume":"25","author":"DE Furst","year":"1998","unstructured":"Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25(1):84\u20138.","journal-title":"J Rheumatol"},{"issue":"5","key":"1630_CR39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/kel451","volume":"46","author":"F Verrecchia","year":"2007","unstructured":"Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, Ertault M, Tiev K, Michel L, Mauviel A, et al. Skin involvement in scleroderma--where histological and clinical scores meet. Rheumatology (Oxford). 2007;46(5):833\u201341.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1630_CR40","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1002\/art.39287","volume":"67","author":"LM Rice","year":"2015","unstructured":"Rice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, Browning JL, Whitfield ML, et al. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2015;67(11):3004\u201315.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1630_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/rheumatology\/kev335","volume":"55","author":"LM Rice","year":"2016","unstructured":"Rice LM, Stifano G, Ziemek J, Lafyatis R. Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis. Rheumatology (Oxford). 2016;55(2):377\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1630_CR42","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/jid.2013.130","volume":"133","author":"M Hinchcliff","year":"2013","unstructured":"Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, Tamaki Z, Lee J, Carns M, Podlusky S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013;133(8):1979\u201389.","journal-title":"J Invest Dermatol"},{"key":"1630_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/B978-0-12-411619-1.00006-9","volume":"537","author":"SD Parlee","year":"2014","unstructured":"Parlee SD, Lentz SI, Mori H, MacDougald OA. Quantifying size and number of adipocytes in adipose tissue. Methods Enzymol. 2014;537:93\u2013122.","journal-title":"Methods Enzymol"},{"issue":"3","key":"1630_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.metabol.2004.09.006","volume":"54","author":"M Inoue","year":"2005","unstructured":"Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metab Clin Exp. 2005;54(3):281\u20136.","journal-title":"Metab Clin Exp"},{"issue":"6","key":"1630_CR45","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/BOR.0000000000000437","volume":"29","author":"RG Marangoni","year":"2017","unstructured":"Marangoni RG, Lu TT. the roles of dermal white adipose tissue loss in scleroderma skin fibrosis. Curr Opin Rheumatol. 2017;29(6):585\u201390.","journal-title":"Curr Opin Rheumatol"},{"issue":"21","key":"1630_CR46","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1021\/bi0159581","volume":"41","author":"LM Leesnitzer","year":"2002","unstructured":"Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002;41(21):6640\u201350.","journal-title":"Biochemistry"},{"issue":"8","key":"1630_CR47","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/art.34424","volume":"64","author":"J Wei","year":"2012","unstructured":"Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J. Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012;64(8):2734\u201345.","journal-title":"Arthritis Rheum"},{"issue":"Pt 1","key":"1630_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1042\/bj3630157","volume":"363","author":"AM Krogsdam","year":"2002","unstructured":"Krogsdam AM, Nielsen CA, Neve S, Holst D, Helledie T, Thomsen B, Bendixen C, Mandrup S, Kristiansen K. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor \u03b4-mediated transactivation. Biochem J. 2002;363(Pt 1):157\u201365.","journal-title":"Biochem J"},{"issue":"4","key":"1630_CR49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cell.2011.10.017","volume":"147","author":"H Yamamoto","year":"2011","unstructured":"Yamamoto H, Williams EG, Mouchiroud L, Canto C, Fan W, Downes M, Heligon C, Barish GD, Desvergne B, Evans RM, et al. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell. 2011;147(4):827\u201339.","journal-title":"Cell"},{"issue":"1","key":"1630_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cell.2013.08.054","volume":"155","author":"P Li","year":"2013","unstructured":"Li P, Spann NJ, Kaikkonen MU, Lu M, Oh DY, Fox JN, Bandyopadhyay G, Talukdar S, Xu J, Lagakos WS, et al. NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell. 2013;155(1):200\u201314.","journal-title":"Cell"},{"issue":"52","key":"1630_CR51","doi-asserted-by":"publisher","first-page":"15090","DOI":"10.1073\/pnas.1610270114","volume":"113","author":"MP Phelps","year":"2016","unstructured":"Phelps MP, Bailey JN, Vleeshouwer-Neumann T, Chen EY. CRISPR screen identifies the NCOR\/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016;113(52):15090\u20135.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1630-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1630-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1630-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:57:46Z","timestamp":1589551066000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1630-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1630-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,11]]},"assertion":[{"value":"4 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the institutional animal care and use committee of Northwestern University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"145"}}